Exploring Galectin-3 as an Emerging Frontier in Biomarker Research for Clinical Trials Approaching Cardiovascular Diseases
ACS Pharmacology & Translational Science · 10.04.2026 · 9 (4) · 771-783
DOI: 10.1021/acsptsci.5c00671 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 11.03.2026. Verfasst von Luís Perpétuo. Beteiligte Einrichtung: iBiMED, Department of Medical Sciences, University of Aveiro, Campus Universitário de Santiago, Aveiro 3810-193, Portugal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funda??o para a Ci?ncia e a Tecnologia.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- iBiMED, Department of Medical Sciences, University of Aveiro, Campus Universitário de Santiago, Aveiro 3810-193, Portugal.
- Cardiovascular R&D Centre - RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Alameda Professor Hernâni Monteiro, Porto 4200-319, Portugal.
ORCID-Profile: Luís Perpétuo
Förderung
- Funda??o para a Ci?ncia e a Tecnologia
Zitieren
APA
Perpétuo, L. (2026). Exploring Galectin-3 as an Emerging Frontier in Biomarker Research for Clinical Trials Approaching Cardiovascular Diseases. ACS Pharmacology & Translational Science, 9(4), 771-783. https://doi.org/10.1021/acsptsci.5c00671
Vancouver
Perpétuo L. Exploring Galectin-3 as an Emerging Frontier in Biomarker Research for Clinical Trials Approaching Cardiovascular Diseases. ACS Pharmacology & Translational Science. 2026;9(4):771-783. doi:10.1021/acsptsci.5c00671
BibTeX
@article{Perptuo2026,
author = {Perpétuo, Luís},
title = {Exploring Galectin-3 as an Emerging Frontier in Biomarker Research for Clinical Trials Approaching Cardiovascular Diseases},
journal = {ACS Pharmacology & Translational Science},
year = {2026},
volume = {9},
number = {4},
pages = {771--783},
doi = {10.1021/acsptsci.5c00671}
}
EUVIMED